Fintech

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine

Prnewswire·April 16, 2026 at 11:00 AM

/PRNewswire/ -- Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

X Money Tests Whether Social Commerce Can Hold Consumer Deposits
PYMNTS
Beaten-down digital asset treasury names lead crypto stock surge as bitcoin hits
CoinDesk
Bitcoin retakes $78,000 as Trump declares Hormuz ‘open and ready for business’
The Block
Sen. Blumenthal presses DOJ and Treasury on Binance monitor amid Iran sanctions
The Block

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine

X Money Tests Whether Social Commerce Can Hold Consumer Deposits

Beaten-down digital asset treasury names lead crypto stock surge as bitcoin hits

Bitcoin retakes $78,000 as Trump declares Hormuz ‘open and ready for business’

Sen. Blumenthal presses DOJ and Treasury on Binance monitor amid Iran sanctions